Commercial Assessment (Buy-Side): Therapeutic
Buy-Side Market Assessment and Forecast for a Commercial Therapeutic
Market Assessment: Biopharma Company
Early-Stage Biopharma Company Needs Strategy and Research Support to Inform Prioritization
Stig Hansen, Kimia Therapeutics
“I’ve worked with the RNA team for over a decade across my current and previous companies. They are our go to valuation firm for valuation because they know the industry, are responsive and understand the nuances that drive transactions just as much as accounting.”
Market Assessment and Valuation: 505(b)(2) Cardiology Drug Therapy
Market Assessment and Valuation for a 505(b)(2) Cardiology Drug Therapy
Fairness Opinion: General Partner-led Secondary Transaction
Royalty Fund Seeks to Make a Final Distribution to Limited Partners
Fairness Opinion: SPAC Target Company Valuation in Biotech
SPAC Seeks Target Company Valuation in Merger Consideration Transaction
Fairness Opinion: De-SPAC Transaction for Inflammatory Disorders Therapeutics Company
SPAC Seeks Independent Valuation of Target
Fairness Opinion: De-SPAC Transaction for T-Cell Therapeutics Company
SPAC Seeks Independent Valuation of Target Company in T-Cell Therapeutics
Fairness Opinion: De-SPAC Transaction for Private Biotech Company
SPAC Seeks Independent Valuation of Target in Mental Health Disorders
